

Amendments to the Claims:

This listing of claims will replace all prior versions, and listings, of claims in the application:

Listing of Claims:

1-6. (Canceled)

7. (Currently Amended; Withdrawn) A method of treating, or reducing the risk of, a human disease or condition in which inhibition of neutrophil elastase activity is beneficial which comprises administering to a person suffering from or susceptible to such a disease or condition, a therapeutically effective amount of a compound of formula (I), as defined in any one of Claims 15-17 ~~1 to 4, 11 and 12~~, or a pharmaceutically acceptable salt thereof.

8-13. (Canceled)

14. (Currently Amended; Withdrawn) A method for the treatment or prophylaxis of ~~an~~ ^a disease or condition selected from adult respiratory distress syndrome (ARDS), cystic fibrosis, ~~pulmonary emphysema~~, chronic obstructive pulmonary disease (COPD), ~~pulmonary hypertension, and asthma, rhinitis, ischemia-reperfusion injury, rheumatoid arthritis, osteoarthritis, cancer, atherosclerosis and gastric mucosal injury~~, which method comprises administering to a person suffering from or susceptible to such a disease or condition, a therapeutically effective amount of a compound of formula (I), as defined in any one of Claims 15-17 ~~1 to 4, 11, and 12~~, or a pharmaceutically acceptable salt thereof.

15 (New) A compound which is 6-methyl-5-(1-methyl-1H-pyrazol-5-yl)-N-{[5-(methylsulfonyl)pyridin-2-yl]methyl}-2-oxo-1-[3-(trifluoromethyl)phenyl]-1,2-dihydropyridine-3-carboxamide, or a pharmaceutically acceptable salt thereof.

16 (New) A compound which is 6-methyl-5-(1-methyl-1H-pyrazol-5-yl)-N-{[5-(methylsulfonyl)pyridin-2-yl]methyl}-2-oxo-1-[3-(trifluoromethyl)phenyl]-1,2-dihydropyridine-3-carboxamide.

17 (New) A compound which is a pharmaceutically acceptable salt of 6-methyl-5-(1-methyl-1H-pyrazol-5-yl)-N- {[5-(methylsulfonyl)pyridin-2-yl]methyl}-2-oxo-1-[3-(trifluoromethyl)phenyl]-1,2-dihydropyridine-3-carboxamide.

18 (New) A pharmaceutical formulation comprising a compound, as defined in any one of Claims 15 to 17 in admixture with a pharmaceutically acceptable diluent or carrier.